We are very close to our $25,000 fundraising goal. Make a last push to get all your donations in. Post it on Facebook, send out emails, Twitter. $1, $10, $25 no donation is too small.

http://www.mwoy.org/pages/ct/ct13/gfrancigqf

Gregory Francis
President
Korchek Technologies
115 Technology Drive, Suite B 206
Trumbull, CT 06611
877-KOR-CHEK (567-2435)
Fax: 203.452.8296
www.Korchek.com

Last chance to do your part to irradicate blood cancer. Fund raising ends this week. Please help.
http://www.mwoy.org/pages/ct/ct13/gfrancigqf

The newest hospital system in New Jersey is officially operating under its own identity — “Inspira Health Network” — and officials threw a christening party on Tuesday.

Inspira is the new brand for South Jersey Healthcare and Underwood-Memorial Hospital. The two hospital systems merged last fall to form an operation with branches in Cumberland, Salem and Gloucester counties as well as more than 5,000 employees.

Andrew
Andrew is twelve years old, in the seventh grade and lives in Old Lyme with his Mom and Dad, Sara and Steve and older brother, Robert and younger sister, Nancy. One month before his 5th birthday, Andrew was diagnosed with Acute Lymphocytic Leukemia (ALL). Andrew was looking forward to riding the school bus with his older bother. It was not until 3 ½ years later that he got to go on the school bus.

Andrew is now an active middle schooler. He plays lacrosse all year long, runs cross country in the fall and takes crew in the summer.

Danielle
Danielle is17 years old and lives in Clinton, CT with her Mom, Mary and sister, Kristen. Just after she turned 4 in 1999 Danielle was diagnosed with Acute Lymphocytic Leukemia (ALL). For three years Danielle spent a lot of time in and out of the hospital; going once a week for chemotherapy and every three weeks would need to stay over night in the hospital for a few days.

Danielle is now a senior in High School because of her experience Danielle wants to be a Nurse Practitioner specializing in pediatric oncology.
http://www.mwoy.org/pages/ct/ct13/gfrancigqf

A cellular therapy has induced remission in a deadly form of adult acute leukemia, Memorial Sloan-Kettering Cancer Center researchers reported in the journal Science Translational Medicine. The therapy uses disabled viruses to program T cells to attack B cells, and it has been used to treat other forms of leukemia. "This is the first report showing some real, clinically beneficial activity in adult acute lymphoblastic leukemia," said Dr. Carl June of the University of Pennsylvania, who is developing a similar treatment

KANSAS CITY, Mo. and PETERBOROUGH, Ontario, March 18, 2013 (GLOBE NEWSWIRE) -- Cerner (CERN) today announced it has acquired Labotix(R) Automation Inc., a leading provider of flexible, open automation solutions for the clinical laboratory setting.
The combination of Cerner Millennium(R), Cerner Copath, and Labotix' Automation will create the most comprehensive set of capabilities on the market to support high volume testing.

To those that have donated to my campaign to eradicate blood cancers, thank you very much.

We are far away from our $25,000 goal and we still need your help. Please visit my donation page and do whatever you can to help the fight against blood cancer. Do it for Andrew, the Boy of the Year, and a survivor thanks to our efforts.

http://www.mwoy.org/pages/ct/ct13/gfrancigqf Gregory Francis

Epic Systems Corp. Chief Executive Officer Judy Faulkner, whose company provides electronic medical records for about half the U.S., said her rivals are attacking her business under cover of easing patient access to data.

The president of Korchek Technologies, Gregory Francis, has been nominated by the Leukemia Lymphoma Society to be Man of the Year.

The Leukemia Lymphoma Society plays a huge role in creating pathways to cure blood cancers. "People talk about curing cancer at some point in the future. But, for LLS, Someday is Today. Contributions made to this organization - through partners, volunteers and generous donors - are driving cures right now. The reality is, if you want to reduce the incidence of lung cancer, stop smoking. If you want to reduce the incidence of melanoma, use sun block. If you want to prevent the incidence of blood cancer, invest in a cure."

Make your Today count by joining me in supporting The Leukemia & Lymphoma Society (LLS) and make a donation Today by clicking the Read More link below.

http://www.mwoy.org/pages/ct/ct13/gfrancigqf

BRAINTREE, Mass. (AP) -- Haemonetics Corp.'s fiscal third quarter earnings plunged 46 percent, as the blood management company invested in a new business and incurred other charges that dragged down results.
The Braintree, Mass., company said Wednesday it earned $9.9 million, or 19 cents per share, in the quarter that ended Dec. 29. That compares with earnings of $18.3 million, or 36 cents per share, in the final quarter of 2011. Excluding one-time costs, adjusted earnings totaled 50 cents per share.
The company's revenue climbed 29 percent to $247.4 million.
Analysts surveyed by FactSet expected, on average, earnings of 47 cents per share on $251.8 million in revenue.
Haemonetics provides blood management systems for health care providers and blood collectors. Revenue excluding the company's recently acquired whole blood business climbed 1 percent to $192.5 million in the quarter.
The company said revenue from its plasma disposables slipped 1 percent to $68.1 million due in part to a tough comparison to the previous year's quarter, which saw strong growth. Platelet disposables revenue climbed 2 percent to $45.1 million.
The company also booked $25 million in costs in the quarter due in part to integration costs and restructuring expenses, mostly related to the acquisition of the whole blood business.
Selling, general and administrative expenses climbed 41 percent to $86.8 million, and the company's research and development cost also rose nearly 15 percent to $10.6 million. Haemonetics said its rise in operating expenses included $14 million for its new whole blood collection business.
The company also reaffirmed its expectation for fiscal 2013 adjusted earnings to range from $1.65 to $1.70 per share. It expects revenue to fall between $888 million and $898 million.
Analysts expect, on average, earnings of $1.69 per share on revenue of $900.3 million.
For fiscal 2014, Haemonetics forecast adjusted profit in the range of $1.95 to $2.05 per share. Revenue is expected to top $1 billion.
Analysts expect, on average, earnings of $2.01 per share on $1.02 billion in revenue.
Haemonetics shares closed Tuesday at $44.44, up about 9 percent since the start of the year. The stock was not trading in the premarket session.
.